Although high expression of p53 protein was detected by immunochemistry, next-generation sequencing (NGS), which was performed on tumor tissue (Thermo Fisher Scientific, Waltham, MA, USA, covering 38 genes including all protein-coding exons of TP53, Illumina MiniSeq platform with an average depth of coverage of 500 ×), did not show a mutation in the p53 gene. This evidence concerns the gene TP53 and neoplasm.